首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1383631

皮肤科药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按皮肤科疾病、给药途径、配销通路、地区和竞争细分

Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Dermatological Diseases, By Route of Administration, By Distribution Channel, by region, and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年全球皮肤科药物市场价值为 182 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年CAGR为9.10%。皮肤科药物是专门为治疗和管理各种皮肤状况和疾病而设计的药物。皮肤科是一门医学专业，专注于诊断、治疗和预防影响皮肤、头髮、指甲和黏膜的疾病和病症。皮肤病药物在解决从常见皮肤病到更复杂的疾病等各种皮肤病问题方面发挥着至关重要的作用。这些是一类较新的皮肤病药物，通常以注射或输注给药。它们用于治疗自体免疫性皮肤病，如牛皮癣、湿疹和寻常型天疱疮。生物製剂针对特定的免疫系统成分来减少发炎和控制症状。有些皮肤病需要影响整个身体的全身性治疗。这些药物包括皮质类固醇、免疫抑制药物和标靶治疗。

痤疮、牛皮癣、湿疹、皮肤癌和皮肤炎等各种皮肤病的高盛行率推动了对皮肤科药物的需求。皮肤状况影响着全球很大一部分人口，从而导致了持续的市场需求。全球老化人口更容易出现皮肤病问题，包括皮肤癌和与年龄相关的皮肤病。随着老年人口的增加，针对与老化相关的疾病的皮肤科药物的需求也随之增加。持续的研究和开发努力发现了针对皮肤病的创新疗法和药物。生物製剂、标靶治疗和新颖配方的进步有助于市场成长。人们对美容皮肤科和美容治疗（例如减少皱纹和嫩肤）的兴趣日益浓厚，增加了美容行业对皮肤科药物和手术的需求。污染和气候变迁等环境因素可能导致皮肤问题。这些环境问题可能会推动对解决与污染相关的皮肤问题的皮肤科药物的需求。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	182亿美元
2028 年市场规模	303.1亿美元
2023-2028 年CAGR	9.10%
成长最快的细分市场	网路药局
最大的市场	北美洲

人口老化加剧

诺华公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
安进公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
艾伯维公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
强生公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
利奥製药公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
礼来公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
葛兰素史克公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
阿斯特捷利康公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
辉瑞公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis
默克公司
- Business Overview
- Company Snapshot
- Products & Services
- Financials (In case of listed companies)
- Recent Developments
- SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录

Product Code: 17585

Global Dermatological Drugs Market has valued at USD 18.20 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.10% through 2028. Dermatological drugs are medications specifically designed for the treatment and management of various skin conditions and disorders. Dermatology is a medical specialty that focuses on the diagnosis, treatment, and prevention of diseases and conditions affecting the skin, hair, nails, and mucous membranes. Dermatological drugs play a crucial role in addressing a wide range of dermatological issues, from common skin conditions to more complex disorders. These are a newer class of dermatological drugs that are often administered as injections or infusions. They are used for autoimmune skin diseases like psoriasis, eczema, and pemphigus vulgaris. Biologics target specific immune system components to reduce inflammation and manage symptoms. Some dermatological conditions require systemic treatments that affect the entire body. These medications can include corticosteroids, immunosuppressive drugs, and targeted therapies.

The high prevalence of various skin conditions, including acne, psoriasis, eczema, skin cancer, and dermatitis, drives the demand for dermatological drugs. Skin conditions affect a significant portion of the global population, leading to a consistent market demand. The global aging population is more prone to dermatological issues, including skin cancers and age-related skin conditions. As the elderly population increases, the demand for dermatological drugs for conditions associated with aging also rises. Ongoing research and development efforts result in the discovery of innovative treatments and drugs for dermatological conditions. Advancements in biologics, targeted therapies, and novel formulations contribute to market growth. The growing interest in cosmetic dermatology and aesthetic treatments, such as wrinkle reduction and skin rejuvenation, boosts the demand for dermatological drugs and procedures in the cosmetic and beauty industry. Environmental factors, such as pollution and climate change, can lead to skin issues. These environmental concerns can drive the demand for dermatological drugs that address pollution-related skin problems.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 18.20 Billion
Market Size 2028	USD 30.31 Billion
CAGR 2023-2028	9.10%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Rising Aging Population

As people age, their skin undergoes natural changes, becoming thinner, less elastic, and more susceptible to damage. This makes the elderly population more prone to various dermatological conditions, including skin cancer, eczema, psoriasis, and age-related skin disorders. Skin cancer risk increases with age, and older individuals are more likely to develop skin cancers such as basal cell carcinoma, squamous cell carcinoma, and melanoma. This drives the demand for dermatological drugs used in the prevention, treatment, and management of skin cancer. Many dermatological conditions are chronic and may worsen with age. Conditions like psoriasis, rosacea, and seborrheic dermatitis often require ongoing treatment, leading to sustained demand for dermatological drugs. Aging is associated with cosmetic concerns such as wrinkles, fine lines, and age spots. The desire to maintain a youthful appearance drives demand for dermatological drugs, including topical treatments, dermal fillers, and botulinum toxin injections.

Chronic itching, a common problem in older adults, can result from various skin conditions or systemic diseases. Dermatological drugs that relieve itching are often prescribed to improve the quality of life for elderly patients. Actinic keratosis, a precancerous skin condition caused by sun exposure, is more common in older individuals. Treating this condition often involves the use of topical dermatological drugs. Older adults are more likely to be taking multiple medications for various health conditions. Some medications can have dermatological side effects, necessitating additional dermatological drug treatments. Older individuals tend to have more frequent healthcare visits, including visits to dermatologists. This increased interaction with healthcare providers results in a higher likelihood of dermatological drug prescriptions. The economic impact of an aging population is substantial, as older adults often have more disposable income to spend on healthcare, including dermatological treatments. The pharmaceutical industry recognizes the growing market potential of dermatological drugs for the aging population. Consequently, there is a focus on developing innovative treatments to address age-related skin conditions. Older individuals are increasingly seeking cosmetic procedures, such as chemical peels and laser therapy, to address age-related skin concerns. These procedures often complement dermatological drug treatments. This factor will help in the development of the Global Dermatological Drugs Market.

Advancements in Dermatological Research

Dermatological research has led to the development of biologic drugs and targeted therapies that specifically address the underlying causes of skin conditions. For example, biologics like TNF-alpha inhibitors and IL-17 inhibitors have revolutionized the treatment of conditions like psoriasis. Advances in genomics and genetics have deepened our understanding of the genetic basis of many skin disorders. Researchers have identified specific genetic mutations associated with conditions like epidermolysis bullosa and ichthyosis, leading to potential gene therapies and precision medicine approaches. Research into skin cancer has led to improved early detection methods, such as dermoscopy and confocal microscopy. Additionally, targeted therapies and immunotherapies have emerged as effective treatments for melanoma and other skin cancers. Research on wound healing and tissue regeneration has resulted in the development of advanced wound dressings, tissue-engineered skin substitutes, and regenerative therapies for conditions like chronic ulcers and burns.

Dermatological research has contributed to the development of cosmetic treatments, including injectables (e.g., dermal fillers and botulinum toxin), laser therapy, and chemical peels, to address aesthetic concerns like wrinkles, fine lines, and pigmentation issues. Ongoing research has led to the development of improved topical treatments and oral medications for various skin conditions, such as acne, eczema, and psoriasis. These treatments offer better efficacy and safety profiles. Advances in immunology and dermatology have led to a better understanding of autoimmune skin diseases like lupus and dermatomyositis. This knowledge has paved the way for targeted immunosuppressive therapies. Research into telemedicine and digital health solutions has expanded access to dermatological care. Teledermatology has enabled remote consultations, diagnosis, and treatment planning, especially in underserved areas. Understanding the skin barrier function and its role in dermatological conditions has led to the development of barrier repair creams and emollients for conditions like atopic dermatitis. Research into the skin microbiome has revealed its importance in maintaining skin health and preventing conditions like acne and dermatitis. This knowledge may lead to microbiome-based therapies in the future. Nanotechnology research has led to the development of nano-formulations for dermatological drug delivery, enhancing the penetration and efficacy of topical treatments. This factor will pace up the demand of the Global Dermatological Drugs Market.

Increased Focus on Aesthetics

Aesthetic dermatology, also known as cosmetic dermatology, encompasses a wide range of procedures and products aimed at enhancing the appearance of the skin and addressing various aesthetic concerns. Aesthetic dermatology offers a variety of anti-aging treatments to reduce the appearance of wrinkles, fine lines, and age-related skin changes. Dermatological drugs such as botulinum toxin (Botox) and dermal fillers are commonly used to achieve a more youthful appearance. Dermatological drugs and procedures are used to rejuvenate the skin by addressing issues like dullness, uneven skin tone, and texture irregularities. Chemical peels, microdermabrasion, and topical retinoids are examples of treatments that promote skin rejuvenation. Conditions like melasma, hyperpigmentation, and age spots can be effectively treated with dermatological drugs like hydroquinone and various topical lightening agents. For individuals with acne scars, dermatological treatments such as laser therapy, chemical peels, and microneedling, along with topical retinoids, can help improve skin texture and reduce scarring.

Dermatological drugs and procedures like CoolSculpting and Kybella are used for non-surgical body contouring to reduce localized fat deposits, such as double chins. Dermatological drugs like minoxidil and finasteride are used to address hair loss and promote hair regrowth. Hair restoration procedures, including platelet-rich plasma (PRP) therapy, are also popular in aesthetic dermatology. For individuals with scars from surgery, injuries, or burns, dermatological treatments such as laser therapy, corticosteroid injections, and silicone gel sheets can help improve the appearance of scars. The use of injectables like dermal fillers and neurotoxins for facial enhancement is widespread in aesthetic dermatology. These products are often administered by dermatologists to address volume loss and facial lines. Dermatological drugs and chemical peels are used to exfoliate the skin, improve texture, and address issues like acne, sun damage, and pigmentation irregularities. Increasingly, individuals are seeking aesthetic treatments to boost their confidence and enhance their appearance. This patient demand drives the growth of the aesthetic dermatology market. Advances in dermatological technology have made aesthetic procedures safer, more effective, and less invasive, contributing to their popularity. The use of cosmeceuticals, which are a combination of cosmetics and pharmaceuticals, has grown. These products often contain active ingredients aimed at improving skin health and appearance. This factor will accelerate the demand of the Global Dermatological Drugs Market.

Key Market Challenges

Resistance and Tolerance

Resistance to topical antibiotics can develop in the treatment of conditions like acne and impetigo. Prolonged use of antibiotics may lead to the development of antibiotic-resistant strains of bacteria on the skin. Resistance to antifungal drugs can occur in the treatment of fungal skin infections, such as dermatophytosis (ringworm) and candidiasis. Fungi can develop resistance to commonly used antifungal agents. Prolonged use of topical corticosteroids can lead to skin thinning and tolerance, where the drug becomes less effective in managing inflammatory skin conditions like eczema and psoriasis. In some cases, acne-causing bacteria can become resistant to antibiotics commonly used in acne treatment. This has led to the development of alternative treatments and the importance of antibiotic stewardship. Some individuals may develop tolerance to OTC products like benzoyl peroxide or salicylic acid when used for acne for acne. This may necessitate a change in treatment or the addition of other therapies. In conditions like psoriasis, the immune system can become resistant to certain treatments, such as topical corticosteroids or phototherapy. This may require the use of different classes of drugs or combination therapies. Dermatologists often use combination therapies that target multiple aspects of a skin condition to reduce the risk of resistance or tolerance. This approach can include combining topical medications, systemic treatments, and non-pharmacological interventions.

Market Competition

Numerous pharmaceutical companies, ranging from large multinational corporations to smaller niche players, compete in the dermatological drugs market. This intense competition can make it challenging for companies to gain market share and maintain pricing power. Competition often leads to price pressure, especially for generic dermatological drugs. As multiple manufacturers produce similar generic products, pricing becomes highly competitive, which can impact profit margins. Some segments of the dermatological drugs market, such as acne treatments and corticosteroid creams, may become saturated with multiple products that offer similar benefits. This saturation makes it challenging for companies to differentiate their offerings and capture market share. Developing innovative dermatological drugs that stand out in the market requires significant research and development investment. Companies must continually innovate to differentiate their products and gain a competitive edge. The regulatory approval process for dermatological drugs can be time-consuming and expensive. Meeting regulatory standards and obtaining approvals for new drugs or formulations is a considerable challenge. The expiration of patents on dermatological drugs can open the door to generic competition, resulting in a loss of market exclusivity and reduced revenue for brand-name drug manufacturers. In some regions, counterfeit or substandard dermatological drugs may enter the market, posing risks to patient safety and eroding trust in the industry. Expanding into new geographic markets requires navigating varying regulatory environments, adapting to local preferences, and competing with established players in those regions. Marketing and promoting dermatological drugs require substantial investments. Companies must effectively communicate the benefits of their products to healthcare providers, dermatologists, and consumers to gain market share.

Key Market Trends

Personalized Medicine

Individuals can respond differently to dermatological treatments due to genetic variations. Personalized medicine seeks to identify these genetic factors to predict treatment responses and outcomes accurately. Pharmacogenomics is the study of how an individual's genetic makeup influences their response to medications. In dermatology, this is particularly relevant for drugs used to treat conditions like psoriasis and acne. Personalized medicine is crucial in the treatment of skin cancers, such as melanoma. Genetic profiling of tumors can guide treatment decisions, including the use of targeted therapies and immunotherapies. Genetic factors play a role in atopic dermatitis (eczema). Personalized medicine can help identify specific genetic markers that influence disease severity and treatment response, allowing for tailored interventions. Genetic testing and molecular diagnostics can help dermatologists select the most appropriate treatment for specific skin conditions, ensuring better outcomes and minimizing side effects. Some companies have developed customized topical treatments based on individual skin characteristics and needs. These formulations are designed to address specific skin concerns, such as acne or hyperpigmentation. Personalized medicine can identify genetic risk factors for skin conditions like skin cancer. Patients with a higher genetic risk may receive more frequent screenings and preventive interventions. By tailoring treatments based on an individual's genetic profile, dermatologists can minimize the risk of adverse effects and optimize treatment safety and efficacy.

Segmental Insights

Dermatological Diseases Insights

In 2022, the Global Dermatological Drugs Market largest share was held by Acne segment and is predicted to continue expanding over the coming years. Acne is one of the most common dermatological conditions worldwide. It affects a large portion of the population, particularly adolescents and young adults. The high prevalence of acne drives demand for dermatological drugs to manage and treat the condition. Acne can range from mild to severe, and the treatment approach varies accordingly. This diversity in the severity of acne allows for a broader range of dermatological drugs, including over the counter (OTC) products and prescription medications, to be used. Many milder cases of acne can be managed with OTC products like benzoyl peroxide creams and salicylic acid cleansers. These products are readily available and contribute to the market share.

Route of Administration Insights

In 2022, the Global Dermatological Drugs Market largest share was held by oral segment and is predicted to continue expanding over the coming years. Oral medications can be used to treat a wide range of dermatological conditions, including systemic conditions like psoriasis, acne, and rosacea. They are not limited to treating surface-level skin issues and can address conditions that affect the entire body. Oral medications are often preferred by patients due to their ease of administration. Patients are generally more compliant with oral drugs compared to topical treatments, as they are familiar with and comfortable taking pills or capsules. Some dermatological conditions, like severe psoriasis or autoimmune skin disorders, require systemic treatment to address the underlying causes. Oral medications can have a systemic effect, reaching affected areas throughout the body. For severe dermatological conditions, oral medications may be the most effective treatment option. They can provide more significant therapeutic effects compared to topical treatments alone.

Distribution Channel Insights

In 2022, the Global Dermatological Drugs Market largest share was held by Retail Pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Retail pharmacies are easily accessible to patients, making it convenient for individuals to fill their dermatological drug prescriptions. Patients can visit a nearby pharmacy to obtain their medications without the need for a hospital visit or specialized clinic. Retail pharmacies typically have a vast network of outlets across urban and rural areas. This extensive distribution network ensures that dermatological drugs are readily available to a wide range of consumers, including those in remote locations. Many dermatological drugs, such as topical creams and ointments for minor skin conditions, are available as OTC products. Retail pharmacies play a crucial role in dispensing these non-prescription medications to consumers without the need for a doctor's prescription. Pharmacists in retail settings often have a wealth of knowledge about medications, including dermatological drugs. They can provide information, instructions on proper usage, and advice on managing side effects, enhancing patient understanding and adherence to treatment regimens.

Regional Insights

The North America region dominates the Global Dermatological Drugs Market in 2022. North America, particularly the United States, has one of the highest healthcare expenditures globally. A substantial portion of this spending goes toward pharmaceuticals, including dermatological drugs. This high level of investment in healthcare infrastructure and pharmaceuticals contributes to market dominance. They have boasts advanced healthcare facilities, including dermatology clinics, research centers, and hospitals. This infrastructure supports the diagnosis and treatment of dermatological conditions, creating a robust market for related drugs. The region has a well-established pharmaceutical industry with several major pharmaceutical companies headquartered in North America. These companies often develop and market dermatological drugs globally, further bolstering the region's dominance. North America has a relatively high prevalence of skin conditions such as acne, psoriasis, eczema, and skin cancer. The demand for dermatological drugs is, therefore, significant due to the need for treatment and management of these conditions.

Key Market Players

Novartis AG

Amgen Inc

AbbVie Inc

Johnson & Johnson

Leo Pharma A/S

Eli Lilly and Company

GlaxoSmithKline Plc

AstraZeneca plc

Pfizer Inc

Merck KGaA

Report Scope:

In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Drugs Market, By Dermatological Diseases:

Acne
Dermatitis
Psoriasis
Skin Cancer
Others

Dermatological Drugs Market, By Route of Administration:

Oral
Parenteral
Topical

Dermatological Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Dermatological Drugs Market, By region:

North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.

Available Customizations:

Global Dermatological Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatological Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral, Topical)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2022)
5.3. Market Map

6. Asia Pacific Dermatological Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Dermatological Diseases
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Dermatological Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Dermatological Diseases
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. India Dermatological Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Dermatological Diseases
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Australia Dermatological Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Dermatological Diseases
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Distribution Channel
- 6.3.4. Japan Dermatological Drugs Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Dermatological Diseases
    - 6.3.4.2.2. By Route of Administration
    - 6.3.4.2.3. By Distribution Channel
- 6.3.5. South Korea Dermatological Drugs Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Dermatological Diseases
    - 6.3.5.2.2. By Route of Administration
    - 6.3.5.2.3. By Distribution Channel

7. Europe Dermatological Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Dermatological Diseases
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Dermatological Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Dermatological Diseases
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. Germany Dermatological Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Dermatological Diseases
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. Spain Dermatological Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Dermatological Diseases
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Dermatological Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Dermatological Diseases
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. United Kingdom Dermatological Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Dermatological Diseases
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Distribution Channel

8. North America Dermatological Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Dermatological Diseases
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Dermatological Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Dermatological Diseases
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. Mexico Dermatological Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Dermatological Diseases
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Canada Dermatological Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Dermatological Diseases
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Distribution Channel

9. South America Dermatological Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Dermatological Diseases
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Dermatological Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Dermatological Diseases
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Dermatological Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Dermatological Diseases
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Dermatological Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Dermatological Diseases
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Dermatological Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Dermatological Diseases
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Dermatological Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Dermatological Diseases
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Dermatological Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Dermatological Diseases
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Dermatological Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Dermatological Diseases
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Dermatological Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Novartis AG
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Amgen Inc
- 16.2.1. Business Overview
- 16.2.2. Company Snapshot
- 16.2.3. Products & Services
- 16.2.4. Financials (In case of listed companies)
- 16.2.5. Recent Developments
- 16.2.6. SWOT Analysis
16.3. AbbVie Inc
- 16.3.1. Business Overview
- 16.3.2. Company Snapshot
- 16.3.3. Products & Services
- 16.3.4. Financials (In case of listed companies)
- 16.3.5. Recent Developments
- 16.3.6. SWOT Analysis
16.4. Johnson & Johnson
- 16.4.1. Business Overview
- 16.4.2. Company Snapshot
- 16.4.3. Products & Services
- 16.4.4. Financials (In case of listed companies)
- 16.4.5. Recent Developments
- 16.4.6. SWOT Analysis
16.5. Leo Pharma A/S
- 16.5.1. Business Overview
- 16.5.2. Company Snapshot
- 16.5.3. Products & Services
- 16.5.4. Financials (In case of listed companies)
- 16.5.5. Recent Developments
- 16.5.6. SWOT Analysis
16.6. Eli Lilly and Company
- 16.6.1. Business Overview
- 16.6.2. Company Snapshot
- 16.6.3. Products & Services
- 16.6.4. Financials (In case of listed companies)
- 16.6.5. Recent Developments
- 16.6.6. SWOT Analysis
16.7. GlaxoSmithKline Plc
- 16.7.1. Business Overview
- 16.7.2. Company Snapshot
- 16.7.3. Products & Services
- 16.7.4. Financials (In case of listed companies)
- 16.7.5. Recent Developments
- 16.7.6. SWOT Analysis
16.8. AstraZeneca plc
- 16.8.1. Business Overview
- 16.8.2. Company Snapshot
- 16.8.3. Products & Services
- 16.8.4. Financials (In case of listed companies)
- 16.8.5. Recent Developments
- 16.8.6. SWOT Analysis
16.9. Pfizer Inc
- 16.9.1. Business Overview
- 16.9.2. Company Snapshot
- 16.9.3. Products & Services
- 16.9.4. Financials (In case of listed companies)
- 16.9.5. Recent Developments
- 16.9.6. SWOT Analysis
16.10. Merck KGaA
- 16.10.1. Business Overview
- 16.10.2. Company Snapshot
- 16.10.3. Products & Services
- 16.10.4. Financials (In case of listed companies)
- 16.10.5. Recent Developments
- 16.10.6. SWOT Analysis